Article Text

Download PDFPDF

COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine
  1. Cheng Lay Teh1,
  2. Yaw Kiet Cheong1,
  3. Wan Rosmaiza Wan Musa2,
  4. Sharifah Aishah Wan Mohd Akbar1,
  5. Noraini Mat Husin3,
  6. Suk Chyn Gun4
  1. 1Department of Medicine, Sarawak General Hospital, Kuching, Sarawak, Malaysia
  2. 2Department of Medicine, Hospital Putrajaya, Putrajaya, Malaysia
  3. 3Department of Medicine, Hospital Ipoh, Ipoh, Perak, Malaysia
  4. 4Department of Medicine, Hospital Tuanku Ja'afar Seremban, Seremban, Negeri Sembilan, Malaysia
  1. Correspondence to Dr Cheng Lay Teh, Medicine, Sarawak General Hospital, Kuching 93450, Malaysia; tehchenglay{at}yahoo.com

Statistics from Altmetric.com

We read with interest the letter by Mathian A et al1 describing the clinical course of COVID-19 in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. The COVID-19 Global Rheumatology Alliance registry2 shows that 19 (17%) of 110 patients with rheumatic diseases who have been diagnosed with COVID-19 as of 1 April 2020 were patients with lupus. Bozzalla Cassione et al,3 Romão et al4 and Ye et al,5 respectively, described patients with SLE in their papers. The latest paper by D’Silva et al reported ten cases of lupus in their cohort.6 We would like to share the clinical course of COVID-19 among patients with SLE in Malaysia.

As of 30 March 2020, there were five cases of SLE from a total of 2626 cases of COVID-19 in Malaysia. Clinical data were obtained through a review of medical records. COVID-19 was …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles